Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2

International Urology and Nephrology

Volumn 50, Issue 2, 2018, Pages 373-382

  Ma, Libin ^a   Li, Hua ^a   Zhang, Shuchao ^a   Xiong, Xiaoling ^a   Chen, Kean ^b   Jiang, Peiwu ^b   Jiang, Kang ^b   Deng, Gang ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

5 6 renal mass reduction; Emodin; Smad7; Smurf 2; TGF 1

Indexed keywords

CREATININE; EMODIN; MESSENGER RNA; PROTEIN SMURF 2; SMAD PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UREA; PROTEIN KINASE INHIBITOR; SMAD7 PROTEIN, RAT; SMURF2 PROTEIN, RAT; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TISSUE; KIDNEY TUMOR; MALE; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; BODY WEIGHT; EMODIN; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; PROTEIN KINASE INHIBITORS; RATS; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN-PROTEIN LIGASES;

EID: 85037714396     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-017-1757-x     Document Type: Article

References (35)

1. Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ (2010) Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 128(1):61–81. https://doi.org/10.1016/j.pharmthera.2010.05.006
2. Fogo AB (2001) Progression and potential regression of glomerulosclerosis. Kidney Int 59(2):804–819. https://doi.org/10.1046/j.1523-1755.2001.059002804.x
3. Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, Arevalo M, Smith JD, Vary CP, Bernabeu C, Lopez-Novoa JM (2001) Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 16(Suppl 1):34–39
4. Nogueira A, JoÃO Pires M, Alexandra Oliveira P (2017) Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo 31(1):1–22. https://doi.org/10.21873/invivo.11019
5. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346(6282):371–374. https://doi.org/10.1038/346371a0
6. Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 13(5):1131–1142
7. Weng L, Wang W, Su X, Huang Y, Su L, Liu M, Sun Y, Yang B, Zhou H (2015) The effect of cAMP-PKA activation on TGF-beta1-induced profibrotic signaling. Cell Physiol Biochem 36(5):1911–1927. https://doi.org/10.1159/000430160
8. Hewitson TD (2009) Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 296(6):F1239–F1244. https://doi.org/10.1152/ajprenal.90521.2008
9. Macias MJ, Martin-Malpartida P, Massague J (2015) Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci 40(6):296–308. https://doi.org/10.1016/j.tibs.2015.03.012
10. Lei XF, Fu W, Kim-Kaneyama JR, Omoto T, Miyazaki T, Li B, Miyazaki A (2016) Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol 64(1):110–117. https://doi.org/10.1016/j.jhep.2015.08.026
11. Zhou X, Zang X, Ponnusamy M, Masucci MV, Tolbert E, Gong R, Zhao TC, Liu N, Bayliss G, Dworkin LD, Zhuang S (2016) Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression. JASN 27(7):2092–2108. https://doi.org/10.1681/asn.2015040457
12. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, Wrana JL (2001) TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 3(6):587–595. https://doi.org/10.1038/35078562
13. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365–1375
14. Yang YC, Lim MY, Lee HS (2003) Emodin isolated from Cassia obtusifolia (Leguminosae) seed shows larvicidal activity against three mosquito species. J Agric Food Chem 51(26):7629–7631. https://doi.org/10.1021/jf034727t
15. Wang JB, Zhao HP, Zhao YL, Jin C, Liu DJ, Kong WJ, Fang F, Zhang L, Wang HJ, Xiao XH (2011) Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS ONE 6(9):e24498. https://doi.org/10.1371/journal.pone.0024498
16. Yang T, Kong B, Kuang Y, Cheng L, Gu J, Zhang J, Shu H, Yu S, Yang X, Cheng J, Huang H (2015) Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1). Int J Clin Exp Pathol 8(3):3418–3425
17. Cha TL, Chuang MJ, Tang SH, Wu ST, Sun KH, Chen TT, Sun GH, Chang SY, Yu CP, Ho JY, Liu SY, Huang SM, Yu DS (2015) Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth. Mol Carcinog 54(3):167–177. https://doi.org/10.1002/mc.22084
18. Yao WY, Zhou YF, Qian AH, Zhang YP, Qiao MM, Zhai ZK, Yuan YZ, Yang SL (2015) Emodin has a protective effect in cases of severe acute pancreatitis via inhibition of nuclear factorkappaB activation resulting in antioxidation. Mol Med Rep 11(2):1416–1420. https://doi.org/10.3892/mmr.2014.2789
19. Kim DY, Kang TB, Shim DW, Sun X, Han JW, Ji YE, Kim TJ, Koppula S, Lee KH (2014) Emodin attenuates A23187-induced mast cell degranulation and tumor necrosis factor-alpha secretion through protein kinase C and IkappaB kinase 2 signaling. Eur J Pharmacol 723:501–506. https://doi.org/10.1016/j.ejphar.2013.09.066
20. Bhadauria M, Nirala SK, Shrivastava S, Sharma A, Johri S, Chandan BK, Singh B, Saxena AK, Shukla S (2009) Emodin reverses CCl induced hepatic cytochrome P450 (CYP) enzymatic and ultrastructural changes: the in vivo evidence. Hepatol Res 39(3):290–300. https://doi.org/10.1111/j.1872-034X.2008.00380.x
21. Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B (2016) The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int 89(5):1049–1061. https://doi.org/10.1016/j.kint.2016.01.016
22. Peng W, Qiu X-Q, Shu Z-H, Liu Q-C, Hu M-B, Han T, Rahman K, Qin L-P, Zheng C-J (2015) Hepatoprotective activity of total iridoid glycosides isolated from Paederia scandens (lour.) Merr. var. tomentosa. J Ethnopharmacol 174:317–321. https://doi.org/10.1016/j.jep.2015.08.032
23. Raij L, Azar S, Keane W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26(2):137–143
24. Abe S, Amagasaki Y, Iyori S, Konishi K, Kato E, Sakaguchi H (1989) Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients. Am J Nephrol 9(1):30–37
25. Ono H, Ono Y (1997) Nephrosclerosis and hypertension. Med Clin N Am 81(6):1273–1288
26. Yoshida Y, Fukuda N, Maeshima A, Yamamoto C, Matsumoto T, Ueno T, Nojima Y, Matsumoto K, Soma M (2011) Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. J Hypertens 29(1):91–101. https://doi.org/10.1097/HJH.0b013e32834000e2
27. Zhang L, Zhang J, Xu C, Zhou X, Wang W, Zheng R, Hu W, Wu P (2015) Lefty-1 alleviates TGF-beta1-induced fibroblast-myofibroblast transdifferentiation in NRK-49F cells. Drug Des Dev Ther 9:4669–4678. https://doi.org/10.2147/dddt.s86770
28. Meng XM, Chung AC, Lan HY (2013) Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (London, England: 1979) 124(4):243–254. https://doi.org/10.1042/cs20120252
29. Lan HY (2003) Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12(1):25–29. https://doi.org/10.1097/01.mnh.0000049812.98789.97
30. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P, Yang J (2012) The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 302(3):F369–F379. https://doi.org/10.1152/ajprenal.00268.2011
31. Wrana JL (2000) Regulation of Smad activity. Cell 100(2):189–192
32. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389(6651):631–635. https://doi.org/10.1038/39369
33. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A (2004) Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 101(23):8687–8692. https://doi.org/10.1073/pnas.0400035101
34. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R (2001) Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 98(3):974–979. https://doi.org/10.1073/pnas.98.3.974
35. Lin X, Liang M, Feng XH (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275(47):36818–36822. https://doi.org/10.1074/jbc.C000580200